Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study.

IF 1.2 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Homeopathy Pub Date : 2024-05-07 DOI:10.1055/s-0044-1779693
Anupriya Chaudhary, Debadatta Nayak, Swati Pandey, Vipul Shastri, Madhuri Kamble, Vidya Pendse, Vismay Prajapati, Brijesh Vaidya, Heenal Rohit, Swaroopa Beedmani, Nutan Presswala, Tejaswini Patole, Ramesh Bawaskar, Vaishali Shinde, Mohua Datta, Gunjan Rai, Umakanta Prusty, Partha Pratim Pal, Siva Prasad Goli, Amulya Ratna Sahoo, K C Muraleedharan, Pooja Prakash, Ashish Mahajan, Anuradha Singh, Reetha Krishnan, Navin Pawaskar, Amit Srivastava, Gouri Devi Ningthoujam, Ravi Kumar Sadarla, Ranjit Sonny, Liyi Karso, Subhamoy Sarkar, Sunil Prasad, Ashish Kumar Shrivastava, Avinash Kumar, Nitesh Kumar, Ch Raveendar, Bsj Raja Kumar, Vspk Sastry, Asha Dasari, K Samson Sundeep, Subhash Kaushik, Padmalaya Rath, Shweta Gautam, Ratan Chandra Shil, Trupti Laxmi Swain, G Ravi Chandra Reddy, S Pradeep, S Stevenson, Gurudev Choubey, Lipipushpa Debata, Anil Khurana
{"title":"Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study.","authors":"Anupriya Chaudhary, Debadatta Nayak, Swati Pandey, Vipul Shastri, Madhuri Kamble, Vidya Pendse, Vismay Prajapati, Brijesh Vaidya, Heenal Rohit, Swaroopa Beedmani, Nutan Presswala, Tejaswini Patole, Ramesh Bawaskar, Vaishali Shinde, Mohua Datta, Gunjan Rai, Umakanta Prusty, Partha Pratim Pal, Siva Prasad Goli, Amulya Ratna Sahoo, K C Muraleedharan, Pooja Prakash, Ashish Mahajan, Anuradha Singh, Reetha Krishnan, Navin Pawaskar, Amit Srivastava, Gouri Devi Ningthoujam, Ravi Kumar Sadarla, Ranjit Sonny, Liyi Karso, Subhamoy Sarkar, Sunil Prasad, Ashish Kumar Shrivastava, Avinash Kumar, Nitesh Kumar, Ch Raveendar, Bsj Raja Kumar, Vspk Sastry, Asha Dasari, K Samson Sundeep, Subhash Kaushik, Padmalaya Rath, Shweta Gautam, Ratan Chandra Shil, Trupti Laxmi Swain, G Ravi Chandra Reddy, S Pradeep, S Stevenson, Gurudev Choubey, Lipipushpa Debata, Anil Khurana","doi":"10.1055/s-0044-1779693","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.</p><p><strong>Methods: </strong> This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.</p><p><strong>Results: </strong> Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (<i>n</i> = 1,556) and 56.81% (<i>n</i> = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; <i>p</i> < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; <i>p</i> < 0.001) and 59.8% (95% CI, 37.80 to 74.10; <i>p</i> < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ<sup>2</sup> = 9.01; <i>p</i> = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong> AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.</p><p><strong>Study registration: </strong> Clinical Trials Registry-India (CTRI/2020/08/027000).</p>","PeriodicalId":13227,"journal":{"name":"Homeopathy","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Homeopathy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1779693","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background:  Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.

Methods:  This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.

Results:  Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (n = 1,556) and 56.81% (n = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; p < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; p < 0.001) and 59.8% (95% CI, 37.80 to 74.10; p < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ2 = 9.01; p = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (p = 0.002).

Conclusion:  AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.

Study registration:  Clinical Trials Registry-India (CTRI/2020/08/027000).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 患者使用预防性 AYUSH 药物与疾病严重程度之间的关系:回顾性队列研究
背景:人们经常研究事先接种疫苗对个人感染后预后的影响。印度政府建议在 2019 年冠状病毒病(COVID-19)第一波大流行期间使用阿育吠陀、瑜伽、尤那尼、悉达和顺势疗法(AYUSH)药物进行预防,这些药物在 2020 年被大众使用。因此,我们开展了一项研究,以观察之前使用阿育王预防药物与 COVID-19 康复者报告的感染后严重程度之间是否存在关联:这是一项回顾性、多中心、队列研究,于 2020 年 8 月 5 日至 11 月 30 日在印度 21 个城市进行。COVID-19康复者的数据不分性别和年龄,采集的信息包括感染前摄入的AYUSH预防药物、疾病严重程度、症状、主诉持续时间等。研究参与者被分为服用和未服用 AYUSH 药物两组。主要的综合结果是疾病的临床过程。次要临床结果是临床康复率和临床康复时间:分析了 5,023 人的数据。半数以上的研究参与者服用了阿育吠陀或顺势疗法预防药物:即分别为 56.85%(n = 1,556 人)和 56.81%(n = 1,555 人)。针对中度/重度 COVID-19 疾病,AYUSH 预防性摄入的总体调整保护效应 (PE) 为 56.7%(95% 置信区间 [CI],48.7 至 63.50;P P 2 = 9.01;P = 0.002)。摄入印度草药组的症状缓解时间比未摄入组平均早 0.3 天(p = 0.002):结论:AYUSH预防剂对COVID-19疾病严重程度的保护具有统计学意义。结论:AYUSH预防性药物对COVID-19疾病的严重程度有明显的统计学保护作用,其中,曾服用顺势疗法或悉达(Siddha)药物对中度/重度疾病有一定的保护作用,并能加快临床康复。要验证本研究的结果,还需要进行实验研究设计的前瞻性研究:研究注册:印度临床试验注册中心(CTRI/2020/08/027000)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Homeopathy
Homeopathy 医学-全科医学与补充医学
CiteScore
3.40
自引率
70.60%
发文量
34
审稿时长
20.1 weeks
期刊介绍: Homeopathy is an international peer-reviewed journal aimed at improving the fundamental understanding and clinical practice of homeopathy by publishing relevant high-quality original research articles, reviews, and case reports. It also promotes commentary and debate on matters of topical interest in homeopathy.
期刊最新文献
Homeopathy at a Turning Point. Homeopathy, Acupuncture and Phytotherapy in the Veterinary Treatment or Prophylaxis of Diseases in Animals: An Overview of Systematic Reviews Solvatochromic Dyes Track a Homeopathic Preparation through Water-Stream Systems in a Program to Control Tick Infestation at a Wild Animal Rehabilitation Center in Brazil Pharmacoeconomic Study of Homeopathic Medicines: A Critical Appraisal of Methods and Conclusions Shows Serious Cause for Concern. Characterisation of Aqueous Ultra-high Homeopathic Potencies: Nanoparticle Tracking Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1